Clinical trialPhase 2Terminated
Study of Gemcitabine and Abraxane for Pancreas Cancer
A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyTesting of combination no longer relevant (Other)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- September 2014
- Expected end
- December 2016
- Enrollment
- 4 participants
- Sites
- 1
- Primary outcomes
- 4 month progression free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 February 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting
Detailed description public domain (ClinicalTrials.gov)
This is an open label Phase II study to evaluate the clinical activity of the combination of gemcitabine and nab-paclitaxel (abraxane) as second line treatment in patients with metastatic pancreatic cancer who have received non-gemcitabine-based chemotherapy in the first line setting. All patients will receive both drugs on Days 1, 8, 15 every 28 days. The hypothesis is that this combination will have a 4-month progression free survival of 70% or higher.